These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34507552)

  • 41. [Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients].
    Baldueva IA; Novik AV; Moiseenko VM; Nekhaeva TL; Danilova AB; Danilov AO; Protsenko SA; Petrova TIu; Uleĭskaia GI; Shchekina LA; Semenova AI; Mikhaĭlichenko TD; Teletaeva GM; Zhabina AS; Volkov NV; Komarov IuI
    Vopr Onkol; 2012; 58(2):212-21. PubMed ID: 22774527
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
    Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
    Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BCG immunotherapy in patients with malignant melanoma.
    Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED
    Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adjuvant immunotherapy for melanoma.
    Humphrey LJ; Taschler-Collins S; Goldfarb PM; Singla O; Volenec FJ
    J Surg Oncol; 1984 Apr; 25(4):303-5. PubMed ID: 6717026
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Where are we with adjuvant therapy of stage III and IV melanoma in 2009?
    Fecher LA; Flaherty KT
    J Natl Compr Canc Netw; 2009 Mar; 7(3):295-304. PubMed ID: 19401062
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel adjuvant options for cutaneous melanoma.
    Dimitriou F; Long GV; Menzies AM
    Ann Oncol; 2021 Jul; 32(7):854-865. PubMed ID: 33771664
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
    Sosman JA; Unger JM; Liu PY; Flaherty LE; Park MS; Kempf RA; Thompson JA; Terasaki PI; Sondak VK;
    J Clin Oncol; 2002 Apr; 20(8):2067-75. PubMed ID: 11956267
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
    Eggermont AMM; Dummer R
    Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): prognostic factors analysis and preliminary results of immunotherapy.
    Balch CM; Smalley RV; Bartolucci AA; Burns D; Presant CA; Durant JR
    Cancer; 1982 Mar; 49(6):1079-84. PubMed ID: 7037155
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunotherapy for Melanoma.
    Moyers JT; Glitza Oliva IC
    Adv Exp Med Biol; 2021; 1342():81-111. PubMed ID: 34972963
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial.
    Hersey P; Coates AS; McCarthy WH; Thompson JF; Sillar RW; McLeod R; Gill PG; Coventry BJ; McMullen A; Dillon H; Simes RJ
    J Clin Oncol; 2002 Oct; 20(20):4181-90. PubMed ID: 12377961
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Journey of the Patient With Melanoma: Understanding Resource Use and Bridging the Gap Between Dermatologist, Surgeon, and Oncologist in Different Health Care Systems.
    Pereira da Veiga CR; Pereira da Veiga C; Drummond-Lage AP; Alves Wainstein AJ; Cristina de Melo A
    J Glob Oncol; 2019 Jul; 5():1-8. PubMed ID: 31283414
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide.
    Elias EG; Suter CM; Fabian DS
    J Surg Oncol; 1997 Jan; 64(1):17-22. PubMed ID: 9040795
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunotherapy for Melanoma.
    Glitza Oliva IC; Alqusairi R
    Adv Exp Med Biol; 2018; 995():43-63. PubMed ID: 30539505
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Approaches to High-Risk Resected Stage II and III Melanoma.
    Yushak M; Mehnert J; Luke J; Poklepovic A
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e207-e211. PubMed ID: 31099653
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Melanoma adjuvant therapy.
    Tarhini AA; Thalanayar PM
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):471-89. PubMed ID: 24880942
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advances in melanoma therapy.
    Johnson TM; Yahanda AM; Chang AE; Fader DJ; Sondak VK
    J Am Acad Dermatol; 1998 May; 38(5 Pt 1):731-41. PubMed ID: 9591818
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent advances in the care of the patient with malignant melanoma.
    Reintgen D; Balch CM; Kirkwood J; Ross M
    Ann Surg; 1997 Jan; 225(1):1-14. PubMed ID: 8998115
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of immunotherapy and surgery for stage IV melanoma.
    Molina G; Kasumova GG; Qadan M; Boland GM
    Cancer; 2020 Jun; 126(11):2614-2624. PubMed ID: 32157676
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changing trends in melanoma treatment and the expanding role of the dermatologist.
    Brown MD; Johnson TM; Swanson NA
    Dermatol Clin; 1991 Oct; 9(4):657-67. PubMed ID: 1934641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.